MULTIPLE MYELOMA

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

Binod Dhakal, MD, discusses the extended follow-up of combination selinexor in the proteasome inhibitor–naive subgroup of patients with multiple myeloma.

A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.

A study reveals significant disparities in access to CAR T therapy for multiple myeloma among racial and ethnic minorities, despite similar treatment outcomes.

During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma patients, regardless of frailty changes.

Iberdomide combined with daratumumab and dexamethasone shows promising results in improving MRD negativity rates for relapsed multiple myeloma patients.

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

A phase 2 study evaluates linvoseltamab's safety and efficacy in high-risk smoldering myeloma, focusing on response rates and MRD negativity.

During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

The FDA approved Bosaya and Aukelso biosimilars, enhancing options for cancer-related bone loss, including in patients with multiple myeloma.

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.

During a live event, Christopher J. Ferreri, MD, discussed findings on dose and schedule modifications of talquetamab in relapsed/refractory multiple myeloma.

Myeloma research faces funding uncertainties, yet collaboration and innovation drive optimism for breakthroughs in treatment and patient care.

During a live event, Christopher J. Ferreri, MD, discussed early- and late-presenting adverse events associated with talquetamab in relapsed/refractory multiple myeloma

The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

Jered Haddad transforms his cancer journey into a mission, cycling in Iceland to raise awareness and funds for multiple myeloma research.

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting in multiple myeloma.

FCARH143, a CAR T-cell therapy, delivered a 100% objective response rate in a phase 1 trial in patients with relapsed/refractory multiple myeloma.

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

George Mulligan, PhD, discusses the ODAC's review of daratumumab for high-risk smoldering multiple myeloma, noting its efficacy in delaying progression but raising questions about patient criteria.